Pharmaceutical formulation containing immunoglobulin

An aqueous pharmaceutical formulation comprising a protein conjugate comprising an immunoglobulin conjugated to a carrier protein, and histidine as a buffering agent, wherein the formulation has a pH of from 7.2 to 7.6 and wherein the carrier protein is keyhole limpet hemocyanin or a subunit thereof.

A set of at least two different protein conjugate preparations, each protein conjugate preparation comprising histidine as a buffering agent and a protein conjugate comprising one or more immunoglobulin moieties conjugated to a carrier protein;

• wherein the immunoglobulin moieties of each element of said set of protein conjugate preparation have identical complementarity determining regions (CDRs);
• and
• wherein different protein conjugate preparations differ in that the immunoglobulin moieties of the protein conjugates have different CDRs.

A method of treating a patient suffering from B-cell non-Hodgkin lymphoma, comprising administering to the patient an aqueous pharmaceutical formulation, said formulation comprising a protein conjugate comprising an immunoglobulin conjugated to a carrier protein, and histidine as a buffering agent;

• wherein the complementarity determining regions of the immunoglobulin conjugated to the carrier protein elicits an immune response in the patient against the non-Hodgkin lymphoma B-cells.

A set of at least two different immunoglobulin preparations, each immunoglobulin preparation comprising histidine as a buffering agent and an immunoglobulin;

• wherein the immunoglobulin molecules of each immunoglobulin preparation have identical complementarity determining regions (CDRs);
• and wherein different immunoglobulin preparations differ in that the immunoglobulins of different preparations have different CDRs.